These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33025730)

  • 1. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.
    Fangusaro J; Mitchell DA; Kocak M; Robinson GW; Baxter PA; Hwang EI; Huang J; Onar-Thomas A; Dunkel IJ; Fouladi M; Warren KE
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28756. PubMed ID: 33025730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
    Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
    J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
    Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
    Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
    Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
    J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
    Tun HW; Johnston PB; DeAngelis LM; Atherton PJ; Pederson LD; Koenig PA; Reeder CB; Omuro AMP; Schiff D; O'Neill B; Pulido J; Jaeckle KA; Grommes C; Witzig TE
    Blood; 2018 Nov; 132(21):2240-2248. PubMed ID: 30262659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.
    Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G
    J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
    Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM
    Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
    Becher OJ; Millard NE; Modak S; Kushner BH; Haque S; Spasojevic I; Trippett TM; Gilheeney SW; Khakoo Y; Lyden DC; De Braganca KC; Kolesar JM; Huse JT; Kramer K; Cheung NV; Dunkel IJ
    PLoS One; 2017; 12(6):e0178593. PubMed ID: 28582410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
    Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S
    Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
    Berg SL; Cairo MS; Russell H; Ayello J; Ingle AM; Lau H; Chen N; Adamson PC; Blaney SM
    J Clin Oncol; 2011 Jan; 29(3):316-23. PubMed ID: 21149673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
    Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.